Secure CheckoutPersonal information is secured with SSL technology.
Free ShippingFree global shipping
No minimum order.
1. Targeting Members of the Epidermal Growth Factor Receptor Family to Improve Response to Chemotherapy
2. Targeting the Hepatocyte Growth Factor Receptor to Overcome Resistance to Targeted Therapies
3. Roles for AXL and MERTK in Resistance to Cytotoxic and Targeted Therapies
4. The JNK Pathway in Drug Resistance
5. Fibroblast Growth Factor Receptor (FGFR) Inhibitors: Enhancing Therapeutic Strategies for Solid Tumors
6. PIK3CA Mutations in Colorectal and Breast Cancer: Impact on Oncogenesis and Response to Nonsteroidal Anti-inflammatory Drugs
7. STAT3 as a Major Contributor to Chemoresistance
8. Targeting the Hippo Pathway to Improve Response to Chemotherapy
9. Modulation of the Epigenome (Methylome) to Improve Chemotherapeutic Efficacy
10. Targeting the ATR Signaling Pathway to Overcome Chemoresistance in Cancer
11. PARP Inhibition to Enhance Response to Chemotherapy
12. Autophagy Inhibition and Chemosensitization in Cancer Therapy
13. Targeting Necroptosis in Anti-Tumor Therapy
Targeting Cell Survival Pathways to Enhance Response to Chemotherapy encompasses recently developed molecular targeting agents and approaches that suppress cell survival signaling. Cell survival signaling attenuates the effectiveness of conventional chemotherapy and numerous mechanisms have been described, and continue to be described, which contribute to cell survival in the face of chemotherapy treatment.
Key pathways leading to chemoresistance emanate from growth factor receptors, PI3K, STAT3, anti-apoptotic Bcl-2 family members, autophagy, and the DNA damage response pathway. New advances have underscored the potential of targeting each of these cell survival mechanisms to improve responsiveness to chemotherapy. This book reviews these recent advances and provides a foundational background and hints of new opportunities for basic, translational, and clinical investigators focused on improving therapeutic responses to chemotherapy.
- Presents cutting-edge agents and approaches with proved success in different model systems that can be translated to a different type of cancer
- Brings updated information to be used to propose new clinical trials investigating innovative strategies for improving responses to chemotherapy
- Provides mechanistic details to help guide the design of laboratory studies associated with clinical trials
Cancer researchers; medical oncologists; clinicians; translational investigators
- No. of pages:
- © Academic Press 2019
- 3rd April 2018
- Academic Press
- Hardcover ISBN:
- eBook ISBN:
Dr. Bonavida is internationally renowned by his expertise and various publications in the field of tumor cell sensitization to chemotherapy and in particular the novel role of Nitric Oxide (NO) donors in chemo-sensitization and reversal of drug resistance. He was the first individual to co-organize the first international workshop on NO and Cancer with Dr. Jean-François Jeannin in Paris. Subsequently, they co-organized three additional conferences on the same topic. The last fourth workshop was held in March in Sevilla, Spain with Dr. Muntane, and the proceedings were published in Redox Biology recently. These conferences focus on NO and derivatives in cancer and their therapeutic applications in resistant cancer.
Professor, Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, USA
Daniel E. Johnson received his undergraduate degrees in chemistry and mathematics from North Park University in Chicago, Illinois. He received his doctoral degree in molecular biology from Princeton University under the mentorship of Dr. Mark A. Bothwell. His postdoctoral research was done under the mentorship of Dr. Lewis T. Williams at the University of California at San Francisco (UCSF). He joined the faculty at the University of Pittsburgh and the University of Pittsburgh Cancer Institute in 1993, where he served as Professor of Medicine and Scientific Director of the Acute Leukemia Working Group. In 2016, he moved to UCSF where he is currently Professor in the Department of Otolaryngology – Head and Neck Surgery. Dr. Johnson has served as a standing member on National Institutes of Health and American Cancer Society study sections and has been a Section Editor for the journal Leukemia since 2001. His research is focused on anti-cancer drug development and the elucidation of cell death and cell survival signaling pathways in head and neck cancer and leukemia. He has additional interests in the development of chemopreventive agents and strategies. Dr. Johnson places particular emphasis on translating laboratory findings to the clinic and has collaborated extensively with physician scientists to initiate and conduct clinical trials in head and neck cancer and acute myeloid leukemia. .
Professor, Department of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, USA